HPGC Renmintongtai Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
HPGC Renmintongtai Pharmaceutical has been growing earnings at an average annual rate of 6.4%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 6.4% per year. HPGC Renmintongtai Pharmaceutical's return on equity is 9.8%, and it has net margins of 2.7%.
Key information
6.4%
Earnings growth rate
6.5%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 6.4% |
| Return on equity | 9.8% |
| Net Margin | 2.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How HPGC Renmintongtai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 10,100 | 274 | 539 | 0 |
| 31 Mar 24 | 10,335 | 299 | 536 | 0 |
| 31 Dec 23 | 10,390 | 292 | 544 | 0 |
| 30 Sep 23 | 10,210 | 313 | 534 | 0 |
| 30 Jun 23 | 10,312 | 312 | 526 | 0 |
| 31 Mar 23 | 9,966 | 290 | 510 | 0 |
| 31 Dec 22 | 9,641 | 264 | 495 | 0 |
| 30 Sep 22 | 9,336 | 235 | 519 | 0 |
| 30 Jun 22 | 9,256 | 247 | 534 | 0 |
| 31 Mar 22 | 9,482 | 283 | 539 | 0 |
| 31 Dec 21 | 9,315 | 277 | 554 | 0 |
| 30 Sep 21 | 9,540 | 239 | 627 | 0 |
| 30 Jun 21 | 9,167 | 201 | 637 | 0 |
| 31 Mar 21 | 8,293 | 137 | 626 | 0 |
| 31 Dec 20 | 8,005 | 145 | 633 | 0 |
| 30 Sep 20 | 7,877 | 199 | 550 | 0 |
| 30 Jun 20 | 7,919 | 207 | 548 | 0 |
| 31 Mar 20 | 8,263 | 242 | 595 | 0 |
| 31 Dec 19 | 8,354 | 267 | 597 | 0 |
| 30 Sep 19 | 7,887 | 265 | 568 | 0 |
| 30 Jun 19 | 7,535 | 264 | 557 | 0 |
| 31 Mar 19 | 7,314 | 262 | 517 | 0 |
| 31 Dec 18 | 7,055 | 258 | 499 | 0 |
| 30 Sep 18 | 7,117 | 248 | 520 | 0 |
| 30 Jun 18 | 7,463 | 249 | 526 | 0 |
| 31 Mar 18 | 7,637 | 258 | 528 | 0 |
| 31 Dec 17 | 8,009 | 254 | 535 | 0 |
| 30 Sep 17 | 8,641 | 239 | 597 | 0 |
| 30 Jun 17 | 8,492 | 238 | 550 | 0 |
| 31 Mar 17 | 8,780 | 227 | 577 | 0 |
| 31 Dec 16 | 9,006 | 225 | 562 | 0 |
| 30 Sep 16 | 8,725 | 196 | 537 | 0 |
| 30 Jun 16 | 8,606 | 160 | 502 | 0 |
| 31 Mar 16 | 8,508 | 140 | 522 | 0 |
| 31 Dec 15 | 8,909 | 139 | 702 | 0 |
| 30 Sep 15 | 8,994 | 162 | 765 | 0 |
| 30 Jun 15 | 9,156 | 163 | 961 | 0 |
| 31 Mar 15 | 9,209 | 200 | 1,109 | 0 |
| 31 Dec 14 | 9,011 | 187 | 1,193 | 0 |
| 30 Sep 14 | 7,682 | 236 | 1,272 | 0 |
| 30 Jun 14 | 6,290 | 163 | 1,325 | 0 |
| 31 Mar 14 | 4,896 | 50 | 1,303 | 0 |
| 31 Dec 13 | 3,177 | 6 | 1,219 | 0 |
| 30 Sep 13 | 3,356 | 68 | 1,299 | 0 |
Quality Earnings: 600829 has high quality earnings.
Growing Profit Margin: 600829's current net profit margins (2.7%) are lower than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600829's earnings have grown by 6.4% per year over the past 5 years.
Accelerating Growth: 600829's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600829 had negative earnings growth (-12.2%) over the past year, making it difficult to compare to the Healthcare industry average (-6.3%).
Return on Equity
High ROE: 600829's Return on Equity (9.8%) is considered low.